|
US7138486B2
(en)
*
|
1986-05-05 |
2006-11-21 |
The General Hospital Corporation |
Insulinotropic hormone derivatives and uses thereof
|
|
US20050272652A1
(en)
|
1999-03-29 |
2005-12-08 |
Gault Victor A |
Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
|
|
US20090281032A1
(en)
*
|
2001-03-01 |
2009-11-12 |
Peter Raymond Flatt |
Modified CCK peptides
|
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
|
RU2385878C2
(ru)
|
2004-02-11 |
2010-04-10 |
Амилин Фармасьютикалз, Инк. |
Пептид, обладающий свойствами амилина (варианты), и его применение (варианты)
|
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
|
US7399744B2
(en)
*
|
2004-03-04 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Methods for affecting body composition
|
|
WO2006049681A2
(en)
*
|
2004-08-30 |
2006-05-11 |
Bayer Pharmaceuticals Corporation |
Selective neuropeptide y2 receptor agonists
|
|
EP2631244A1
(en)
*
|
2004-10-08 |
2013-08-28 |
Amylin Pharmaceuticals, Inc. |
Amylin family polypeptide-6 (AFP-6) analogs and methods of making and using them
|
|
WO2007055728A1
(en)
*
|
2005-11-01 |
2007-05-18 |
Amylin Pharmaceuticals, Inc. |
Treatment of obesity and related disorders
|
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
|
BRPI0606992A2
(pt)
|
2005-02-11 |
2009-07-28 |
Amylin Pharmaceuticals Inc |
análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
|
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
|
BRPI0612471A2
(pt)
*
|
2005-05-05 |
2016-09-06 |
Cadila Healthcare Ltd |
novos compostos como agonistas glp-1
|
|
EP1912666A2
(en)
*
|
2005-07-22 |
2008-04-23 |
Amylin Pharmaceuticals, Inc. |
Use of amylin and amylin agonists as cardioprotective or myoprotective agents
|
|
CN101296942A
(zh)
*
|
2005-08-11 |
2008-10-29 |
安米林药品公司 |
具有可选择特性的杂合多肽
|
|
BRPI0614649A2
(pt)
|
2005-08-11 |
2011-04-12 |
Amylin Pharmaceuticals Inc |
polipeptìdeos hìbridos com propriedades selecionáveis
|
|
EP2330124B1
(en)
|
2005-08-11 |
2015-02-25 |
Amylin Pharmaceuticals, LLC |
Hybrid polypeptides with selectable properties
|
|
PL1767545T3
(pl)
|
2005-09-22 |
2010-04-30 |
Biocompatibles Uk Ltd |
Polipeptydy fuzyjne GLP-1 (glukagonopodobny peptyd-1) o zwiększonej odporności na peptydazy
|
|
WO2007055743A2
(en)
*
|
2005-11-01 |
2007-05-18 |
Amylin Pharmaceuticals, Inc. |
Treatment of obesity and related disorders
|
|
CN101389648B
(zh)
*
|
2006-02-22 |
2013-07-17 |
默沙东公司 |
肽胃泌酸调节素衍生物
|
|
JP5252435B2
(ja)
*
|
2006-03-15 |
2013-07-31 |
ノボ・ノルデイスク・エー／エス |
アミリン誘導体
|
|
WO2007109354A2
(en)
*
|
2006-03-21 |
2007-09-27 |
Amylin Pharmaceuticals, Inc. |
Peptide-peptidase inhibitor conjugates and methods of using same
|
|
ATE444741T1
(de)
|
2006-05-10 |
2009-10-15 |
Biocompatibles Uk Ltd |
Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung
|
|
MX2008014870A
(es)
|
2006-05-30 |
2009-02-12 |
Intarcia Therapeutics Inc |
Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
|
|
US20100009907A1
(en)
*
|
2006-07-06 |
2010-01-14 |
Amylin Pharmaceuticals, Inc. |
Glucagon-Like Peptides and Uses Thereof
|
|
CA2657347C
(en)
|
2006-07-10 |
2014-11-18 |
Paion Uk Limited |
Short-acting benzodiazepine salts and their polymorphic forms
|
|
EP2049081B1
(en)
|
2006-08-09 |
2012-11-14 |
Intarcia Therapeutics, Inc. |
Osmotic delivery systems and piston assemblies
|
|
AU2007284365A1
(en)
*
|
2006-08-17 |
2008-02-21 |
Amylin Pharmaceuticals, Inc. |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
|
EP1972349A1
(en)
*
|
2007-03-21 |
2008-09-24 |
Biocompatibles UK Limited |
GLP-1 fusion peptides conjugated to polymer(s), their production and use
|
|
HRP20130259T1
(hr)
|
2007-04-23 |
2013-04-30 |
Intarcia Therapeutics, Inc. |
Suspenzijske formulacije inzulinotropnih peptida i njihove uporabe
|
|
AU2008274845A1
(en)
*
|
2007-07-06 |
2009-01-15 |
Theratechnologies Inc. |
Bifunctional fusion proteins of the alpha-melanocyte stimulating hormone (alpha-MSH) and atrial natriuretic protein (ANP) and uses in hypertension and acute kidney injury
|
|
DK2240155T3
(da)
|
2008-02-13 |
2012-09-17 |
Intarcia Therapeutics Inc |
Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
|
|
EP2303313B1
(en)
|
2008-05-21 |
2015-10-28 |
Amylin Pharmaceuticals, LLC |
Exendins to lower cholestrol and triglycerides
|
|
CN102197049B
(zh)
|
2008-10-21 |
2015-03-25 |
诺沃-诺迪斯克有限公司 |
胰岛淀粉样多肽衍生物
|
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
|
WO2010118384A2
(en)
|
2009-04-10 |
2010-10-14 |
Amylin Pharmaceuticals, Inc. |
Amylin agonist compounds for estrogen-deficient mammals
|
|
EP2435061A4
(en)
|
2009-05-28 |
2013-03-27 |
Amylin Pharmaceuticals Inc |
DAMPING GLP-1 RECEPTOR AGONIST COMPOUNDS
|
|
SMT201700583T1
(it)
|
2009-09-28 |
2018-01-11 |
Intarcia Therapeutics Inc |
Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
|
|
AU2010321587A1
(en)
|
2009-11-23 |
2012-06-07 |
Amylin Pharmaceuticals, Inc. |
Polypeptide Conjugate
|
|
GB201001333D0
(en)
|
2010-01-27 |
2010-03-17 |
Imp Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
|
EA023925B1
(ru)
|
2010-04-27 |
2016-07-29 |
Зилэнд Фарма А/С |
Пептидные конъюгаты агонистов рецептора glp-1 и их применение
|
|
EP2450039A1
(en)
|
2010-11-08 |
2012-05-09 |
PAION UK Ltd. |
Dosing regimen for sedation with CNS 7056 (Remimazolam)
|
|
MX377589B
(es)
|
2010-12-16 |
2025-03-10 |
Novo Nordisk As |
Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
|
|
JP2014504588A
(ja)
|
2010-12-22 |
2014-02-24 |
アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー |
膵島細胞移植のためのｇｌｐ−１受容体アゴニスト
|
|
GB201101459D0
(en)
|
2011-01-27 |
2011-03-16 |
Imp Innovations Ltd |
Novel compounds and thier effects on fedding behaviour
|
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
|
JP2014521594A
(ja)
|
2011-05-25 |
2014-08-28 |
アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー |
長持続期間デュアルホルモンコンジュゲート
|
|
MX2014005351A
(es)
*
|
2011-11-03 |
2014-05-28 |
Zealand Pharma As |
Conjugados de gastrina peptidicos de agonistas de receptor glp-1.
|
|
CN104203266B
(zh)
|
2012-03-22 |
2017-12-26 |
诺和诺德股份有限公司 |
Glp‑1肽组合物及其制备
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
HK1211232A1
(en)
|
2012-12-21 |
2016-05-20 |
Sanofi |
Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
|
|
AR094963A1
(es)
|
2013-03-04 |
2015-09-09 |
Ono Pharmaceutical Co |
Reacción de oxidación excelente en el índice de conversión
|
|
WO2014158900A1
(en)
*
|
2013-03-14 |
2014-10-02 |
Indiana University Research And Technology Corporation |
Insulin-incretin conjugates
|
|
JP6672140B2
(ja)
|
2013-05-02 |
2020-03-25 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１化合物の経口投薬
|
|
MX2016005556A
(es)
|
2013-11-06 |
2016-07-15 |
Zealand Pharma As |
Compuestos agonistas duales de gip-glp-1 y procedimientos.
|
|
AU2014345570B2
(en)
|
2013-11-06 |
2019-01-24 |
Zealand Pharma A/S |
Glucagon-GLP-1-GIP triple agonist compounds
|
|
US10583172B2
(en)
|
2013-11-15 |
2020-03-10 |
Novo Nordisk A/S |
HPYY(1-36) having a beta-homoarginine substitution at position 35
|
|
MX369818B
(es)
|
2013-11-15 |
2019-11-22 |
Novo Nordisk As |
Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
|
|
WO2015086728A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
|
TW201609799A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重ｇｌｐ－１／ｇｉｐ受體促效劑
|
|
WO2015086733A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
|
EP3080152A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
|
CN103665148B
(zh)
*
|
2013-12-17 |
2016-05-11 |
中国药科大学 |
一种可口服给药的降糖多肽及其制法和用途
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
WO2016044224A1
(en)
|
2014-09-15 |
2016-03-24 |
Amgen Inc. |
Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
|
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
|
US10253078B2
(en)
|
2014-10-29 |
2019-04-09 |
Zealand Pharma A/S |
GIP agonist compounds and methods
|
|
AR103954A1
(es)
|
2015-03-18 |
2017-06-14 |
Zealand Pharma As |
Análogos de amilina
|
|
TWI799849B
(zh)
|
2015-04-24 |
2023-04-21 |
美商安美基公司 |
治療或預防偏頭痛之方法
|
|
US10925639B2
(en)
|
2015-06-03 |
2021-02-23 |
Intarcia Therapeutics, Inc. |
Implant placement and removal systems
|
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
|
MA43205A
(fr)
|
2015-06-12 |
2018-09-19 |
Novo Nordisk As |
Composés pyy sélectifs et leurs utilisations
|
|
AR105284A1
(es)
|
2015-07-10 |
2017-09-20 |
Sanofi Sa |
Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
|
|
KR102844773B1
(ko)
|
2015-12-23 |
2025-08-13 |
암젠 인크 |
위 억제 펩티드 수용체 (gipr)에 대한 결합 단백질을 glp-1 효능제와 조합하여 사용하여 대사 장애를 치료하거나 개선시키는 방법
|
|
RU2760007C2
(ru)
|
2016-05-16 |
2021-11-22 |
Интарсия Терапьютикс, Инк. |
Полипептиды, селективные к рецепторам глюкагона, и способы их применения
|
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
|
EP4316595A3
(en)
*
|
2016-09-02 |
2024-04-17 |
Christopher J. Soares |
Use of cgrp receptor antagonists in treating glaucoma
|
|
TWI784968B
(zh)
|
2016-09-09 |
2022-12-01 |
丹麥商西蘭製藥公司 |
澱粉素類似物
|
|
US11285180B2
(en)
|
2016-12-06 |
2022-03-29 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
|
|
AU2017371516C1
(en)
|
2016-12-09 |
2021-09-02 |
Zealand Pharma A/S |
Acylated GLP-1/GLP-2 dual agonists
|
|
CN110225762A
(zh)
|
2017-01-03 |
2019-09-10 |
因塔西亚制药公司 |
包括glp-1受体激动剂的连续施用和药物的共同施用的方法
|
|
BR112019014588A2
(pt)
|
2017-01-17 |
2020-02-18 |
Amgen Inc. |
Método de tratamento ou amenização de distúrbios metabólicos usando agonistas do receptor de glp-1 conjugados a antagonistas para receptor do peptídeo inibidor gástrico (gipr)
|
|
CN110831969B
(zh)
|
2017-06-20 |
2024-06-21 |
安进公司 |
使用抑胃肽受体（gipr）结合蛋白与glp-1激动剂的组合治疗或改善代谢障碍的方法
|
|
MX2019015544A
(es)
|
2017-06-21 |
2020-07-28 |
Amgen Inc |
Metodo para tratar o mejorar trastornos metabolicos con proteinas de fusion de agonistas del receptor de glp-1/proteinas de union antagonistas para el receptor peptidico inhibidor gastrico (gipr).
|
|
PL3746111T3
(pl)
|
2018-02-02 |
2024-01-15 |
Novo Nordisk A/S |
Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
|
|
AU2019246983B2
(en)
|
2018-04-02 |
2025-12-18 |
Amgen Inc. |
Erenumab compositions and uses thereof
|
|
TWI847981B
(zh)
*
|
2018-04-25 |
2024-07-11 |
比利時商健生藥品公司 |
類升糖素肽1 (glp-1)融合肽偶合環狀酪酪肽接合物及其用途
|
|
US11780900B2
(en)
|
2018-04-25 |
2023-10-10 |
Janssen Sciences Ireland Unlimited Company |
Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
|
|
US11970523B2
(en)
*
|
2018-07-25 |
2024-04-30 |
China Pharmaceutical University |
Long-acting oxyntomodulin hybrid peptide, preparation method therefor, and application thereof
|
|
AR116632A1
(es)
|
2018-10-11 |
2021-05-26 |
Intarcia Therapeutics Inc |
Polipéptidos análogos de la amilina humana y sus métodos de uso
|
|
EP3934679A1
(en)
|
2019-03-08 |
2022-01-12 |
Amgen Inc. |
Growth differentiation factor 15 combination therapy
|
|
US12384825B2
(en)
|
2019-04-01 |
2025-08-12 |
Syracuse University |
Monomeric peptide multi-agonist targeting the GLP1 receptor and NPY receptors
|
|
KR102288716B1
(ko)
*
|
2019-10-30 |
2021-08-12 |
경상남도 |
항비만 효능을 갖는 펩타이드 및 이의 용도
|
|
EP4058047A1
(en)
|
2019-11-11 |
2022-09-21 |
Boehringer Ingelheim International GmbH |
Npy2 receptor agonists
|
|
UA130066C2
(uk)
|
2020-08-07 |
2025-10-29 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Розчинні агоністи рецепторів npy2
|
|
IL300620B2
(en)
*
|
2020-09-24 |
2025-12-01 |
Gubra As |
Ham15-52 analogues with improved amylin receptor (hamy3r) potency
|
|
TWI850611B
(zh)
*
|
2020-12-18 |
2024-08-01 |
丹麥商諾佛 儂迪克股份有限公司 |
Glp-1及澱粉素受體之共促效劑
|
|
TW202400632A
(zh)
*
|
2021-03-03 |
2024-01-01 |
美商美國禮來大藥廠 |
長效澱粉素受體促效劑及其用途
|
|
CN113929737B
(zh)
*
|
2021-10-20 |
2024-07-23 |
中国科学院香港创新研究院再生医学与健康创新中心 |
一种多肽及其作为cck受体激动剂/拮抗剂的应用
|
|
WO2024123812A1
(en)
|
2022-12-05 |
2024-06-13 |
Shattuck Labs, Inc. |
Fusion proteins for the treatment of cardiometabolic diseases
|
|
US12533394B2
(en)
*
|
2023-11-15 |
2026-01-27 |
Glycomantra Inc. |
Compositions and methods for treating metabolic disorders
|